Antiviral Therapy for Chronic Hepatitis B in Pregnancy

Abstract

The management of chronic hepatitis B (CHB) during pregnancy remains a challenge and involves various aspects of maternal–fetal care. Despite the standard immunoprophylaxis, a significant portion of infants born to highly viremic mothers remain infected with hepatitis B virus (HBV). Emerging data suggest that antiviral therapy in the third trimester can prevent immunoprophylaxis failure. To minimize fetal exposure to antiviral agents, antiviral therapy during pregnancy should be reserved for mothers with advanced disease or who are at risk for hepatic decompensation. Current safety data suggest that lamivudine, telbivudine, or tenofovir may be used during pregnancy. However, the timing in initiating antiviral therapy requires careful assessment of risks and benefit. The authors provide a systematic review of the features of HBV during pregnancy, risk factors for vertical transmission, and evidence-based data on antiviral use during pregnancy. They propose an algorithm to assess the need of antiviral treatment and monitor mothers with CHB.

Keywords

vertical transmission - hepatitis B in pregnancy - fetal exposure - antiviral treatment - drug safety

• References

• 1 World Health Organization. Hepatitis B Fact sheet, July 2012. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ . Accessed November 1 , 2012
• 2 Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis 2007; 11 (4) 945-963
• 3 Weinbaum CM, Williams I, Mast EE , et al; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57 (RR-8) 1-20
• 4 European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1) 167-185
• 5 Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3) 661-662
• 6 Tong MJ, Pan CQ, Hann HW , et al. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011; 56 (11) 3143-3162
• 7 Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol 2007; 47 (1) 46-50
• 8 Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001; 184 (7) 1514-1518 , discussion 1518–1520
• 9 Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43 (5) 771-775
• 10 Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 2011; 18 (7) e394-e398
• 11 Safir A, Levy A, Sikuler E, Sheiner E. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 2010; 30 (5) 765-770
• 12 Wong S, Chan LY, Yu V, Ho L. Hepatitis B carrier and perinatal outcome in singleton pregnancy. Am J Perinatol 1999; 16 (9) 485-488
• 13 Lobstein S, Faber R, Tillmann HL. Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. Digestion 2011; 83 (1-2) 76-82
• 14 Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 2011; 31 (8) 1163-1170
• 15 Terazawa S, Kojima M, Yamanaka T , et al. Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res 1991; 29 (1) 5-9
• 16 Tan HH, Lui HF, Chow WC. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int 2008; 2 (3) 370-375
• 17 Söderström A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003; 35 (11-12) 814-819
• 18 Yang YB, Li XM, Shi ZJ, Ma L. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. World J Gastroenterol 2004; 10 (15) 2305-2306
• 19 ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15 (1) 37-41
• 20 Lin HH, Wu WY, Kao JH, Chen DS. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. J Gastroenterol Hepatol 2006; 21 (3) 605-609
• 21 Rawal BK, Parida S, Watkins RP, Ghosh P, Smith H. Symptomatic reactivation of hepatitis B in pregnancy. Lancet 1991; 337 (8737) 364
• 22 Nguyen G, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009; 29 (7) 755-764
• 23 Xu WM, Cui YT, Wang L , et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16 (2) 94-103
• 24 Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19 (2) e18-e25
• 25 Xu DZ, Yan YP, Choi BC , et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67 (1) 20-26
• 26 Wiseman E, Fraser MA, Holden S , et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190 (9) 489-492
• 27 Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170 (6) 1418-1423
• 28 Pan CQ, Duan ZP, Bhamidimarri KR , et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10 (5) 452-459
• 29 Han GR, Cao MK, Zhao W , et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55 (6) 1215-1221
• 30 Pan CQ, Han GR, Jiang HX , et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10 (5) 520-526
• 31 Feibus KB. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use. J Med Toxicol 2008; 4 (4) 284-288
• 32 Antiviral Pregnancy Registry (APR). Antiviral Pregnancy Registry Interim Report 1, January 1989 through 31 January 2012. Available at: http://APregistry.com 2012. Accessed November 1, 2012
• 33 Pan C, Zhang H, Pang Q , et al. Real world data on the efficacy and safety of telbivudine or lamivudine use in late pregnancy for the prevention of perinatal transmission of hepatitis B virus to the infants. Hepatology 2012; 56 (S1) 368A
• 34 Shah I. Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy. Ann Trop Paediatr 2009; 29 (4) 257-261
• 35 Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22 (9) 782-789
• 36 Gibb DM, Kizito H, Russell EC , et al; DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9 (5) e1001217
• 37 Viganò A, Mora S, Giacomet V , et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16 (8) 1259-1266
• 38 Siberry GK, Williams PL, Mendez H , et al; Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26 (9) 1151-1159
• 39 Han GR, Jiang XH, Zhao W , et al. Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission of chronic hepatitis B in highly viremic mothers. Hepatology 2011; 54 (S4) 479A
• 40 Pan CQ, Mi LJ, Bunchorntavakul C , et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012; 57 (9) 2423-2429
• 41 U.S. National Institutes of Health ClinicalTrials.gov. Available at: http://clinicaltrialsgov/show/NCT01488526 . Accessed November 1, 2012
• 42 Keeffe EB, Dieterich DT, Han SH , et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6 (12) 1315-1341 , quiz 1286
• 43 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53 (3) 774-780
• 44 Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int 2010; 30 (2) 275-283
• 45 Nie R, Jin L, Zhang H, Xu B, Chen W, Zhu G. Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization. Fertil Steril 2011; 95 (5) 1667-1671
• 46 Wong VC, Lee AK, Ip HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. Br J Obstet Gynaecol 1980; 87 (11) 958-965
• 47 Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975; 2 (7938) 740-741
• 48 Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002; 99 (6) 1049-1052
• 49 Van Rompay KK, Hamilton M, Kearney B, Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother 2005; 49 (5) 2093-2094